Joel E. Gallant

31.4k total citations · 8 hit papers
156 papers, 15.8k citations indexed

About

Joel E. Gallant is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Joel E. Gallant has authored 156 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Infectious Diseases, 96 papers in Virology and 40 papers in Epidemiology. Recurrent topics in Joel E. Gallant's work include HIV/AIDS drug development and treatment (105 papers), HIV Research and Treatment (96 papers) and HIV/AIDS Research and Interventions (87 papers). Joel E. Gallant is often cited by papers focused on HIV/AIDS drug development and treatment (105 papers), HIV Research and Treatment (96 papers) and HIV/AIDS Research and Interventions (87 papers). Joel E. Gallant collaborates with scholars based in United States, United Kingdom and Spain. Joel E. Gallant's co-authors include Richard E. Chaisson, Robert F. Siliciano, Richard D. Moore, Thomas C. Quinn, Diana Finzi, Theodore C. Pierson, Karen Chadwick, Jeanne Keruly, Andrew Cheng and Stephen J. Gange and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Joel E. Gallant

154 papers receiving 15.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

1997 2.4k citations Joseph B. Margolick, Joel E. Gallant et al. profile →
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1999 1.6k citations Janet D. Siliciano, Stephen J. Gange et al. profile →
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>

2004 1.1k citations Joel E. Gallant profile →
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2016 478 citations Michael S. Saag, Joseph J. Eron et al. profile →
Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

2013 363 citations Joel E. Gallant, Michael A. Horberg et al. Clinical Infectious Diseases profile →
Antiretroviral Treatment of Adult HIV Infection

2014 352 citations Joseph J. Eron, Joel E. Gallant et al. profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Joel E. Gallant, Anthony Mills et al. The Lancet profile →

Peers

Countries citing papers authored by Joel E. Gallant

Since Specialization

Citations

This map shows the geographic impact of Joel E. Gallant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel E. Gallant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel E. Gallant more than expected).

Fields of papers citing papers by Joel E. Gallant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel E. Gallant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel E. Gallant. The network helps show where Joel E. Gallant may publish in the future.

Co-authorship network of co-authors of Joel E. Gallant

This figure shows the co-authorship network connecting the top 25 collaborators of Joel E. Gallant. A scholar is included among the top collaborators of Joel E. Gallant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel E. Gallant. Joel E. Gallant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure 2017 ·Hepatology ·Fred Poordad, Stanislas Pol, Armen Asatryan, Marı́a Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert Reindollar, Stuart C. Gordon, Stephen Pianko, Michael Fried, David Bernstein, Joel E. Gallant, Chih‐Wei Lin, Lei Yang, Teresa I. Ng, Preethi Krishnan, (unknown), Jens Kort, Federico Mensa	105
2	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial 2017 ·The Lancet HIV ·Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, (unknown), Magdalena E. Sobieszczyk, Joel E. Gallant, Hong‐Van Tieu, Winkler G. Weinberg, David A. Margolis, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Elizabeth Gould, Alex R. Rinehart, Kimberly Y. Smith, William Spreen	164
3	Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis 2017 ·The Journal of Infectious Diseases ·Joel E. Gallant, Priscilla Y. Hsue, Sanatan Shreay, Nicole Meyer	161
4	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
5	Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials 2014 ·Clinical Infectious Diseases ·Jean B. Nachega, Jean-Jacques Parienti, Olalekan A. Uthman, Robert Gross, David W. Dowdy, Paul E. Sax, Joel E. Gallant, Michael J. Mugavero, Edward J. Mills, Thomas P. Giordano	269
6	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results 2013 ·The Journal of Infectious Diseases ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew Cheng	84
7	Short Communication: CD4 Cell Count Increases During Successful Treatment of Graves' Disease with Methimazole in HIV-Infected Patients on Antiretroviral Therapy 2012 ·AIDS Research and Human Retroviruses ·Arata Honda, (unknown), (unknown), Joel E. Gallant, Todd T. Brown	5
8	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	335
9	Essential Components of Effective HIV Care: A Policy Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition 2011 ·Clinical Infectious Diseases ·Joel E. Gallant, Adaora A. Adimora, (unknown), Michael A. Horberg, Mari M. Kitahata, E. Byrd Quinlivan, James L. Raper, Peter A. Selwyn, (unknown)	65
10	Should antiretroviral therapy be started earlier? 2007 ·Current HIV/AIDS Reports ·Joel E. Gallant	4
11	Stability of the Latent Reservoir for HIV‐1 in Patients Receiving Valproic Acid 2007 ·The Journal of Infectious Diseases ·Janet D. Siliciano, Jun Lai, (unknown), (unknown), Hao Zhang, Joseph B. Margolick, Joel E. Gallant, Joseph Cofrancesco, Richard D. Moore, Stephen J. Gange, Robert F. Siliciano	141
12	Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients 2007 ·AIDS ·Richard Haubrich, (unknown), Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag, Ben Van Baelen, Éric Lefebvre	96
13	Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects 2005 ·The Journal of Infectious Diseases ·Joel E. Gallant, Allan Rodríguez, Winkler G. Weinberg, Benjamin Young, Daniel S Berger, Michael L. Lim, Qiming Liao, Lisa Ross, Judy Johnson, Mark S. Shaefer, (unknown)	109
14	High-Risk Behavior and Potential Transmission of Drug-Resistant HIV Among Injection Drug Users 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Ajay K. Sethi, David D. Celentano, Stephen J. Gange, Joel E. Gallant, David Vlahov, Homayoon Farzadegan	24
15	Tenofovir Disoproxil Fumarate 2003 ·Clinical Infectious Diseases ·Joel E. Gallant, Stan Deresinski	118
16	Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance 2003 ·Clinical Infectious Diseases ·(unknown), David D. Celentano, Stephen J. Gange, Richard D. Moore, Joel E. Gallant	378
17	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2002 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	152
18	Initial therapy of HIV infection 2002 ·Journal of Clinical Virology ·Joel E. Gallant	51
19	When to consider corticosteroid therapy for HIV-infected patients 1999 ·Joel E. Gallant	1
20	Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens 1999 ·AIDS ·Christopher S. Hall, Charles Raines, Scott H. Barnett, Richard D. Moore, Joel E. Gallant	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact